Table 1 Clinical data of the CCR2 high... | American Society of Hematology

Table 1

Clinical data of the CCR2^high and CCR2^low patients

Category	CCR2^high, % (n = 29)	CCR2^low, % (n = 177)	P
Bone lesions: major structural damage or > 3 osteolyses	55*	36*	.03
Age ≥ 65 y	21	19	NS
κ light chain	64	64	NS
λ light chain	36	34	NS
Nonsecreting	0	2	NS
IgA subtype	21	25	NS
B2M ≤ 3.5 mg/L	72	62	NS
B2M > 5.5 mg/L	7	17	NS
Lactate dehydrogenase ≥ 240 IU/L	18	24	NS
Albumin < 35 g/L	21	35	NS
Hemoglobin < 10 g/dL	10*	32*	.01
C-reactive protein ≥ 5 mg/L	38	36	NS

Category	CCR2^high, % (n = 29)	CCR2^low, % (n = 177)	P
Bone lesions: major structural damage or > 3 osteolyses	55*	36*	.03
Age ≥ 65 y	21	19	NS
κ light chain	64	64	NS
λ light chain	36	34	NS
Nonsecreting	0	2	NS
IgA subtype	21	25	NS
B2M ≤ 3.5 mg/L	72	62	NS
B2M > 5.5 mg/L	7	17	NS
Lactate dehydrogenase ≥ 240 IU/L	18	24	NS
Albumin < 35 g/L	21	35	NS
Hemoglobin < 10 g/dL	10*	32*	.01
C-reactive protein ≥ 5 mg/L	38	36	NS

A total of 206 newly diagnosed patients with MM were separated into 2 subgroups according to CCR2 gene expression in myeloma cells to optimize the difference in patients' proportion with major structural damage or > osteolyses using the Maxstat package. The 2 subgroups represent patients with high (ie, CCR2 signal > 3735, CCR2^high) or low (ie, CCR2 signal ≤ 3735, CCR2^low) CCR2 expression. Data are the percentages of patients within each subgroup with the indicated clinical or biologic parameter.

Statistically significantly different (χ2 test, P ≤ .05).

View Large

This Feature Is Available To Subscribers Only